Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Net Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Net Margin for 7 consecutive years, with 14482.19% as the latest value for Q3 2025.

  • Quarterly Net Margin changed N/A to 14482.19% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 7276.84% through Dec 2025, down 851858.0% year-over-year, with the annual reading at 4416.22% for FY2025, 680354.0% down from the prior year.
  • Net Margin for Q3 2025 was 14482.19% at Outlook Therapeutics, up from 1338.75% in the prior quarter.
  • The five-year high for Net Margin was 14482.19% in Q3 2025, with the low at 1338.75% in Q2 2025.